Notice of Intent to Sole Source to Fisher Scientific Company LLC for Culture Media, Various Reagents, and Supplies
Archived on March 18, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:30 AM EDT
- Posted
- March 10, 2026
- Notice type
- Presolicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH OLAO
- Place of performance
- Bethesda, Maryland, 20892
- Last updated
- Nov 2, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 26-001885
- Notice ID
- 518f176e5f744efcbe8da27a57668033
Description
Notice of Intent to Sole Source to Fisher Scientific Company LLC for Culture Media, Various Reagents, and Supplies
NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing
Product Service Code (PSC): 6640 – Laboratory Equipment and Supplies
Place of Performance:
National Institutes of Health
Clinical Center
10 Center Drive
Bethesda, MD 20892
POTS: 26-001885
Description
This notice is issued for informational purposes only and does not constitute a request for quotations. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Clinical Center, Office of Acquisition and Logistics Management (OALM), on behalf of the Department of Laboratory Medicine (DLM), Microbiology Service, intends to award a firm-fixed-price contract on a sole-source basis to Fisher Scientific Company LLC for the provision of culture media, various reagents, and laboratory supplies.
The anticipated period of performance is:
-
Base Year: March 20, 2026 – September 30, 2026
-
Option Year 1: October 1, 2026 – September 30, 2027
-
Option Year 2: October 1, 2027 – September 30, 2028
The Microbiology Service requires the establishment of a purchase agreement for culture media, reagents, and supplies necessary to support clinical patient testing at the NIH Clinical Center.
The Department of Laboratory Medicine requires continued access to specialized culture media, reagents, and related supplies from Fisher Scientific Company LLC to support routine and specialized microbiological testing performed by the Microbiology Service. While similar materials may be available from other vendors, these alternatives have demonstrated variable performance during internal laboratory validations and published evaluations.
The laboratory has standardized its testing procedures using specific products supplied through Fisher Scientific and has completed the required clinical validations in accordance with Centers for Medicare & Medicaid Services (CMS) regulations for use in patient care. These validated procedures are compliant with Clinical Laboratory Improvement Amendments (CLIA) requirements and the laboratory’s Individualized Quality Control Plans (IQCPs).
To maintain compliance with regulatory requirements and ensure consistent patient testing results, media quality, performance, and tolerance limits must remain consistent across manufacturing lots and shipments. Establishing a purchase agreement with Fisher Scientific will allow the Microbiology Service to sustain uninterrupted testing operations, maintain regulatory compliance, and ensure reliable and timely diagnostic results for patients treated at the NIH Clinical Center.
Minimum Specifications
The contractor shall provide culture media, reagents, and laboratory supplies according to the operational needs of the Microbiology Service. Orders will be placed on an as-needed basis throughout the period of performance.
The contractor shall:
-
Provide technical support for all reagents and supplies and their performance characteristics at no additional cost to the Government.
-
Provide the following for requested reagents and/or supplies:
-
Same lot release per order per item, when requested
-
Latest available expiration date
-
-
Supply culture media, reagents, and supplies in a timely manner throughout the period of performance.
-
In the event of a partial shipment, contact the Microbiology Service to verify whether to ship the available items or place the order on backorder until the requested quantity from a single manufacturing lot is available.
Authority
This acquisition is being conducted in accordance with:
FAR 13.106-1(b)(1) – Soliciting from a Single Source
For acquisitions not exceeding the Simplified Acquisition Threshold (SAT), contracting officers may solicit from one source when the contracting officer determines that only one source is reasonably available to meet the Government’s requirements.
Acquisitions conducted under FAR Part 13 – Simplified Acquisition Procedures are exempt from the competition requirements of FAR Part 6.
Responses
This notice is not a request for quotations.
However, interested parties may submit capability statements demonstrating their ability to provide culture media, reagents, and laboratory supplies equivalent to those required by the Department of Laboratory Medicine.
Capability statements must clearly demonstrate the ability to:
-
Provide validated clinical microbiology culture media and reagents suitable for CLIA-regulated laboratory testing
-
Maintain consistent lot quality and manufacturing controls
-
Provide reliable supply and timely delivery for clinical laboratory operations
-
Provide technical support for laboratory reagents and supplies
The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement based upon responses received is solely within the discretion of the Government.
Submission Instructions
Capability statements or comments referencing POTS: 26-001885 must be submitted electronically to:
Shasheshe Goolsby
Team Leader
Hospital and Laboratory Support Division
Office of Acquisition and Logistics Management (OALM)
NIH Clinical Center
Email: shasheshe.goolsby@nih.gov
Responses must be received no later than March 17 at 12:30 AM EST.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
- 3Version 3PresolicitationArchivedCurrent
Notice of Intent to Sole Source to Fisher Scientific Company LLC for Culture Media, Various Reagents, and Supplies
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers. | - | Combined Synopsis | 11/18/2026 |
See attached Sources Sought Notice. | - | Market Research | 10/28/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
Redacted J&A posted in accordance with RFO 6.301 | - | Sole Source / J&A | Open |
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | - | Pre-Solicitation | 11/11/2026 |
Additional Details
Solicitation Number
26-001885
Archive Date
Mar 18, 2026
Office Address
BETHESDA, MD, 20892